Serban Ghiorghiu

R&D BioPharmaceuticals
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial.

Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial.

Journal: BMJ open

Published: October 28, 2025

Implementation of digital health technology in clinical trials: the 6R framework.

Implementation of digital health technology in clinical trials: the 6R framework.

Journal: Nature medicine

Published: August 16, 2023

Diversity of US participants in AstraZeneca-sponsored clinical trials.

Diversity of US participants in AstraZeneca-sponsored clinical trials.

Journal: Contemporary clinical trials

Published: August 04, 2023

Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges.

Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 09, 2023

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

Journal: JAMA oncology

Published: May 01, 2020

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 26, 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 22, 2017

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Journal: The New England journal of medicine

Published: December 14, 2016

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: July 18, 2016

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Journal: The New England journal of medicine

Published: April 30, 2015

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: July 10, 2014

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Journal: Cancer discovery

Published: June 05, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026